W. Taylor Kimberly, MD PhD is Chief of the Division of Neurocritical Care, and a stroke and critical care neurologist in the Department of Neurology.
Clinically, he primarily cares for patients in the Neuroscience ICU as part of an integrated and multi-disciplinary team, coordinating care with Neurosurgery and Neuroendovascular specialists. He sees Neuro ICU patients in follow-up in outpatient clinic as part of the NeuroRecovery clinical team. He serves on several hospital-based and national committees that focus on clinical guideline development and care improvement.
Dr. Kimberly's research group is located in the Center for Genomic Medicine (Kimberly Lab), and studies metabolomic and neuroimaging biomarkers of subarachnoid hemorrhage, stroke and cerebral edema. The goal of his research is to identify novel pathways and candidate therapeutic targets for the treatment of acute brain injury. Dr. Kimberly has co-led multi-site, randomized, placebo-controlled trials in the prevention of brain edema, and currently co-leads an international phase 3 trial evaluating the safety and efficacy of intravenous glibenclamide for the prevention of brain edema after large hemispheric stroke.
Clinical Interests:
Treats:
Mass General Neurology: Neuroscience Intensive Care Unit
55 Fruit St.
Lunder Building
6th Floor
Boston, MA 02114
Phone: 857-238-5600
Mass General Neurology: NeuroRecovery Clinic
55 Fruit St.
Lunder Building
6th Floor
Boston, MA 02114
Phone: 617-726-8459
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Kimberly's laboratory is devoted to the study of secondary brain injury after stroke. His research group (Kimberly Lab) develops novel tools, including neuroimaging analysis, metabolomics and proteomics, to identify clinically relevant markers of stroke. Promising candidates may become diagnostic or prognostic biomarkers. However, the primary goal of the laboratory is to leverage biomarkers to study the biological and pathological events following acute brain injury and to bring new treatments to patients through multicenter clinical trials.
